Description
KPV Capsules | Alpha-MSH C-Terminal Tripeptide — Anti-Inflammatory Research
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH), retaining the primary anti-inflammatory activity of the parent peptide. It acts as a melanocortin-1 receptor (MC1R) agonist and is also studied for direct intracellular NF-κB inhibition independent of receptor binding. The oral capsule format (4mg per capsule, 60 capsules) is particularly relevant for GI tract-targeted inflammatory research protocols.
Mechanism of Action
- MC1R agonism — activates melanocortin-1 receptor, initiating cAMP-mediated anti-inflammatory cascades
- NF-κB inhibition — directly suppresses nuclear factor kappa-B translocation independent of receptor signaling
- Cytokine suppression — reduces IL-1β, TNF-α, and IL-6 in macrophage and intestinal epithelial cell models
- Gut barrier protection — shown to reduce intestinal permeability and tight junction disruption in IBD models
Research Areas
KPV is studied in inflammatory bowel disease, intestinal permeability, skin inflammation, and systemic anti-inflammatory research. The oral capsule format is especially relevant for colonic delivery studies. Commonly paired with BPC-157 capsules for comprehensive GI integrity research panels.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. K. Hoffmann –
KPV capsules for our oral anti-inflammatory gut research. Content purity >99%. Capsule weight uniformity ±2% of label. COA detailed. Our oral IBD model showed expected NF-κB pathway inhibition.
S. Adesanya –
4mg KPV capsules — ideal for our oral gut inflammation research. Content confirmed. COA thorough. Our intestinal epithelial model showed expected anti-inflammatory activity via oral delivery.
P. Christensen –
Good KPV capsules. Content >98.5%. Capsule uniformity acceptable. COA comprehensive. Convenient format for oral gut permeability and inflammation research.